The National Institute for Pharmaceutical Research and Development (NIPRD), Idu, Abuja, was set up by Decree 30 of 1987 to bridge precisely the gap that had stranded *Fagara* and so many other 1970s university-laboratory leads — bench science to GMP product. Niprisan is the flagship; the four candidates below are the next rank.
Niprifan — a *Cassia alata*-based antifungal cream, validated against *Trichophyton* and *Microsporum* dermatophytes. Registered with NAFDAC in the mid-2000s and produced in small batches; never reached mass distribution because no commercial partner picked it up after the Xechem collapse soured NIPRD on licensing.
Niprimal — a standardised aqueous extract of *Nauclea latifolia* and *Cymbopogon citratus* combination, screened for antimalarial activity in murine models and Phase I in healthy volunteers. Sat behind WHO's adoption of artemisinin combination therapies in 2001, which removed the procurement window any new plant-derived antimalarial would have needed to enter.
Niprid — a *Hibiscus sabdariffa* (zobo) extract validated as a mild antihypertensive in a NIPRD-led study at the National Hospital Abuja. Reached pilot production; remains uncommercialised.
Niprisalt — a potassium-chloride substitute for sodium chloride developed for hypertensive patients, formulated to mimic table-salt mouthfeel. Pilot batches produced, no mass marketing.
The pattern is the one set out in the Niprisan deepdive: the science clears its bar; the commercial bridge does not get built. Each of these products would, in any country with a guaranteed-procurement public-health system, be a line item in the federal pharmacy formulary.